Advanced Health Intelligence secures R & D Grant and Short Term Loan Facility

Advanced Health Intelligence Ltd (ASX:AHI) (NASDAQ:AHI) ('the Company' or 'AHI') is pleased to advise that it has secured a Research & Development Grant ('R & D Grant') in relation to AHI's research & development expenditure during the financial year ended 30 June 2022 and a short term loan facility ('facility') in the amount of $1 million.

The Company is to receive an R & D Grant of $1,209,344 in recognition of the Company spending $2,780,102 in research and development expenditure for the year ended 30 June 2022.

The Company is currently in negotiations with parties in regard to a convertible note funding round of up to USD$10,000,000 and has also secured a facility from an entity controlled by Mr Peter Wall ('lender'), under which $1 million has been drawn down by AHI for working capital purposes. No interest is payable on the facility, provided the amount drawn down from the facility is fully repaid by 15 March 2023 (maturity date). If the amount drawn down from the facility is not repaid by the maturity date, interest at the mate of 15% per annum will be applied on the amount owing until the outstanding amount is fully repaid.

In lieu of no interest being payable on amount drawn down from the facility, the Company has agreed to allot and issue 500,000 fully paid ordinary shares to the lender.

For more information, contact:

Scott Montgomery	**Simon Durack JP**
Chief Executive Officer	**Company Secretary & CFO**
Advanced Health Intelligence Ltd	**Advanced Health Intelligence Ltd**
E: admin@ahi.tech	E: admin@ahi.tech

*This announcement has been approved by the board of Advanced Health Intelligence Ltd.

About Advanced Health Intelligence Ltd

Advanced Health Intelligence delivers scalable health assessment, risk stratification and digital triage to healthcare providers, insurers, employers and government agencies.

Since 2014, AHI has been delivering Health-tech innovation using smartphones, starting with the world's first on-device body dimensioning capability. AHI has developed a patented technology, securing and bringing forth the next frontier in digitizing healthcare with a suite of componentized solutions.

AHI has assembled a world-class team of machine learning, AI, and computer vision experts along with medically trained data scientists to develop a comprehensive mobile-phone-based risk assessment tool culminating in:

• Body dimension and composition assessment to identify the comorbidities of obesity, such as diabetes risk estimates.
• Blood biomarker prediction, including HbA1C, HDL, LDL, and 10-year mortality risk.
• Transdermal Optical Imaging to return vital signs and cardiovascular disease risk estimates.
• On-device dermatological skin identification with over 588 skin conditions across 133 categories (Inc. Melanoma).
• Personalised non-therapeutic health coaching to improve daily habits and build health literacy.

With a focus on impact at scale, AHI is proud to showcase this milestone in digital healthcare transformation, delivering a biometrically driven triage solution, all accessible on and via a smartphone. With these advanced technologies, AHI helps its partners identify risk across their consumers, to then triage them into right-care pathways for proactive health management at a population scale.

This delivery of proprietary capabilities ushers forth an era of cost-effective health accessibility for billions of smartphone users worldwide. In doing so, AHI endeavours to put the power of possibilities in the hands of global communities, empowering people to take control of their journey to better health outcomes.

For more information, please visit: www.ahi.tech